OBJECTIVE: Obesity in pregnancy bears unique maternal and fetal risks, including an increased risk for gestational diabetes and metabolic perturbations in the offspring. Obesity has also been associated with chronic inflammation, including elevated levels of IL-6 and TNF-alpha. Levels of serum lipopolysaccharides (LPS) rise with increased gut permeability, and have been implicated in driving this inflammation, a phenomenon called metabolic endotoxemia (ME). GLP-2, a proglucagon-derived peptide believed to be integral in maintaining the integrity of the intestine in the face of LPS -mediated endotoxemia. However, variations in these likely molecular mediators in pregnancies among normal, obese, and women with excess weight gain have not yet been explored. We hypothesized that obesity and/or excess weight gain in pregnancy would be associated with an increase in maternal and neonatal markers of ME, as well as GLP-2. STUDY DESIGN: Paired maternal and neonatal (cord blood) serum samples (n¼161) were obtained from our pregnancy biobank repository. Serum levels of LPS, endotoxin core antibody (EndoCAbIgM), and GLP-2 were measured by ELISA. IL-6 and TNF-alpha were measured using a Milliplex assay. Results were stratified by maternal body mass index (BMI), diabetes, and gestational weight gain (GWG). RESULTS: Maternal IL-6 is significantly decreased in the obese, diabetic cohort compared with the non-obese, non-diabetics (95.28 vs. 99.48 pg/mL, p¼0.047) while GLP-2 is significantly increased (1.92 vs. 2.89 ng/mL, p¼0.026). Neonatal TNF-alpha is significantly decreased in the obese cohort compared to the non-obese (12.43 vs. 13.93 pg/mL, p¼0.044). Maternal GLP-2 is significantly increased in women with excess GWG compared with those with normal GWG (2.27 vs. 1.48 ng/mL, p¼0.014, Figure) . We further found that neonatal IL-6 and TNF-alpha are negatively correlated with maternal BMI (-0.186, p¼0.036 and -0.179, p¼0.044 respectively), and that maternal and neonatal IL-6 showed a positive correlation (0.348, p<0.001). CONCLUSION: While we observed altered levels of markers of inflammation (IL-6 and TNF-alpha) with maternal obesity and diabetes, no changes in LPS or endoCAb-IgM were observed. We hypothesize that the increased GLP-2 levels in maternal serum in association with excess GWG may protect against ME in pregnancy.
STUDY DESIGN:
We conducted a survey of all SMFM members in 2018. The primary outcomes were the risk of death at which the member would recommend TOP or consider it to be medicallyindicated. The primary exposures were demographic information, experience, and answers to questions regarding the safety of TOP. Chi-squared analyses were utilized in order to determine if significant differences existed between groups. RESULTS: Of the 2,685 SMFM members, 98 responded. 49% would recommend TOP for a patient with greater than 10% chance of death, and 78% would consider TOP to be medically indicated anyone with greater than 1% chance of death. There were significant regional differences, and 49% percent of respondents had misconceptions regarding TOP. Region of origin, residency, and misconceptions regarding TOP were associated with the opinion that TOP should be recommended (OR 2.49, p¼0.046) or considered medically indicated (OR 3.54, p¼0.004) at higher risk of maternal death than 10% or 1%, respectively. 46.9% of respondents overestimated the highest reported risk of death after second trimester TOP in the United States by one thousand fold or more. CONCLUSION: Significant differences of opinion exist amongst MFM physicians regarding the risk of death at which to recommend or consider a TOP medically indicated. MFMs who are well informed about TOP were more likely to recommend TOP or consider it to be medically-indicated at lower chances of mortality than 10% and 1%, respectively.
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